Company intelligence / Profile preview
OncBioMune Pharmaceuticals, Inc.
Baton Rouge, Louisiana, United Statesoncbiomune.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 2
01
Overview
ProscaVax has completed Phase 1a trial showing it is non-toxic and can lower PSA levels. The company was moving forward with Phase 2 trials for prostate cancer patients in the "Active Surveillance" category. The Phase 2 trial was scheduled to commence in December 2018 at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard University.[1][6][7]
- Therapeutic areas
- Oncology
- Modalities
- VaccinesImmunotherapyTargeted therapiesBiosimilars
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Department of Defense Navy Cancer Vaccine Program
Beyond the preview
Go deeper on OncBioMune Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncBioMune Pharmaceuticals, Inc..